Search research articles
Contact Us
Filters
Showing results (21-30 of 53) with videos related to
Page
of 6
Sort By:
Antiviral Research
|
February 8, 2018
Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors
Tomokazu Yoshinaga, Takahiro Seki, Shigeru Miki, et al.
AIDS (London, England)
|
July 1, 2011
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
Sherene Min, Louis Sloan, Edwin DeJesus, et al.
British Journal of Clinical Pharmacology
|
February 5, 2023
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies
Rashmi Mehta, Chakradhar V Lagishetty, Konstantinos Angelis, et al.
Current Urology
|
July 14, 2023
Clinical and prostate multiparametric magnetic resonance imaging findings as predictors of general and clinically significant prostate cancer risk: A retrospective single-center study
Matteo Massanova, Rebecca Vere, Sophie Robertson, et al.
Human Pathology
|
March 13, 2012
Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor
Lewis MacKenzie, Pamela McCall, Sophia Hatziieremia, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 23, 2018
Radiosynthesis and in vivo evaluation of [<sup>11</sup>C]MOV as a PET imaging agent for COX-2
Jaya Prabhakaran, Mark Underwood, Francesca Zanderigo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 21, 2025
Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile
Luise Rogg, Mark Underwood, Nathan Hanan, et al.
Antiviral Therapy
|
September 11, 2019
Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review
Vani Vannappagari, Leigh Ragone, Cassidy Henegar, et al.
Lancet (London, England)
|
January 10, 2018
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
Josep M Llibre, Chien-Ching Hung, Cynthia Brinson, et al.
Research Square
|
November 3, 2021
COVID-19 induces neuroinflammation and loss of hippocampal neurogenesis
Robyn Klein, Allison Soung, Cheick Sissoko, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 53) with videos related to
Sort By:
Page
of 6
Antiviral Research
|
February 8, 2018
Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors
Tomokazu Yoshinaga, Takahiro Seki, Shigeru Miki, et al.
AIDS (London, England)
|
July 1, 2011
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
Sherene Min, Louis Sloan, Edwin DeJesus, et al.
British Journal of Clinical Pharmacology
|
February 5, 2023
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies
Rashmi Mehta, Chakradhar V Lagishetty, Konstantinos Angelis, et al.
Current Urology
|
July 14, 2023
Clinical and prostate multiparametric magnetic resonance imaging findings as predictors of general and clinically significant prostate cancer risk: A retrospective single-center study
Matteo Massanova, Rebecca Vere, Sophie Robertson, et al.
Human Pathology
|
March 13, 2012
Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor
Lewis MacKenzie, Pamela McCall, Sophia Hatziieremia, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 23, 2018
Radiosynthesis and in vivo evaluation of [<sup>11</sup>C]MOV as a PET imaging agent for COX-2
Jaya Prabhakaran, Mark Underwood, Francesca Zanderigo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 21, 2025
Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile
Luise Rogg, Mark Underwood, Nathan Hanan, et al.
Antiviral Therapy
|
September 11, 2019
Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review
Vani Vannappagari, Leigh Ragone, Cassidy Henegar, et al.
Lancet (London, England)
|
January 10, 2018
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
Josep M Llibre, Chien-Ching Hung, Cynthia Brinson, et al.
Research Square
|
November 3, 2021
COVID-19 induces neuroinflammation and loss of hippocampal neurogenesis
Robyn Klein, Allison Soung, Cheick Sissoko, et al.
Page
of 6